73 results on '"De Nicola S."'
Search Results
2. OC.16.6: APPLICATION OF MACHINE LEARNING MODEL-3P TO PREDICT PORTAL HYPERTENSION IN PATIENT WITH HEPATOCELLULAR CARCINOMA
3. T.07.4: ACTIVE HCV OR HBV INFECTION DOES NOT IMPACT ON CLINICAL OUTCOMES IN PATIENTS WITH HEPATOCELLULAR CARCINOMA
4. Myosteatosis is not associated with complications or survival in HCC patients undergoing transarterial embolization
5. High Incidence of sepsis caused by MDR bacteria in patients undergoing Percutaneous biliary drainage for the treatment of biliary obstruction
6. OC.12.5 MYOSTEATOSIS IS NOT ASSOCIATED WITH COMPLICATIONS OR SURVIVAL IN HCC PATIENTS UNDERGOING TRANS ARTERIAL EMBOLIZATION
7. Liver transplant recipients with Covid-19: results from an Italian multicenter cohort
8. Liver transplant candidates and SARS-CoV-2 infection: Results from an Italian multicenter cohort
9. COVID-19-related thrombotic microangiopathy in a cirrhotic patient
10. Early liver transplantation in active drinkers with and without alcoholic hepatitis: a monocentric case series
11. Transjugular intrahepatic portosystemic shunt is an effective and safe treatment of cirrhotic patients with portal vein thrombosis or cavernoma
12. 03:18 PM Abstract No. 75 Portal cavernoma revascularization through splenic access in symptomatic portal hypertension: a paradigm shift in interventional radiology
13. HEV infection: an emerging disease. One year observation in a tertiary care center in Milan
14. Clinical presentation and etiological spectrum of idiopathic non-cirrhotic portal hypertension (INCPH): data from the Italian Registry
15. High-quality GeV-scale electron bunches with the Resonant Multi-Pulse Ionization Injection
16. Risk and outcome of hepatitis B virus (HBV) reactivation during chronic hepatitis C treatment with direct-acting antivirals (DAAs) in patients with HCV-related advanced fibrosis: A single-center experience
17. Changes of indications for liver transplantation in the era of direct acting antiviral therapy in Europe
18. Hepatitis C Virus: Determinants Of Patients’ Management Costs
19. [New Carbon Materials 2016, 31(6): 621–627]. Microstructures of carbon nanoscrolls characterized by polarized micro–Raman spectroscopy
20. Transjugular intrahepatic portosystemic shunt is a safe and effective approach in cirrhotic patients with splanchnic vein thrombosis
21. TM6SF2, MBOAT7 and PNPLA3 genotypes in patients with untreated HCV chronic hepatitis and alcohol intake
22. Characterization of piezoresistive properties of graphene-supported polymer coating for strain sensor applications
23. Microstructures of carbon nanoscrolls characterized by polarized micro–Raman spectroscopy
24. TM6SF2 and MBOAT7 genotype to determine alcohol-related liver damage in patients with HCV chronic hepatitis
25. A multicentre prospective study response to treatment in genotype 3 and 1b infected patients with sickest liver cirrhosis: SVR 4 is not a reliable measure
26. Semi-analytical fluid study of the laser wake field excitation in the strong intensity regime
27. Formation and stability of a hollow electron beam in the presence of a plasma wake field driven by an ultra-short electron bunch
28. The concept of coupling impedance in the self-consistent plasma wake field excitation
29. ITPA deficiency does not predict anaemia during Ribavirin containing DAA all oral regimens for HCV
30. The role of serum alphafetoprotein determination in HCV-cirrhosis after antiviral treatment
31. Inosine Triphosphatase Deficiency does not Predict Anaemia during Ribavirin Containing DAA All Oral Regimens for HCV
32. Core Antigen Quantification to Monitor Treatment Efficacy in Patients with Chronic Hepatitis C Receiving Directly Acting Antivirals
33. P0751 : Polymorphisms in the FAS promoter region are not associated with fibrosis progression in HCV-1 and -4 patients
34. Missense variant in interferon-λ4 gene identifies HCV-1 infected patients carrying the unfavorable IL28B (T) allele with improved viral kinetics
35. OC-21 The association of IL28B genotype with the histological features of chronic hepatitis C is HCV genotype dependent
36. 1080 LOW RATES OF SVR TO PEGINTERFERON PLUS RIBAVIRIN IN HCV GENOTYPE 1 IL28B RS12979860 CC CIRRHOTIC PATIENTS WITHOUT RAPID VIROLOGICAL RESPONSE
37. OC-31 Low rates of SVR to peg-interferon plus ribavirin in HCV genotype 1 IL28B rs12979860 CC cirrhotic patients without rapid virological response
38. T-31 Effect of the PNPLA3 I148M polymorphism on the outcome of peg-interferon plus ribavirin treatment in chronic hepatitis C
39. Spiking control by means of “phase feedback” in FitzHugh–Nagumo circuits
40. OC7 AN IL28B POLYMORPHISM PREDICTS PEGYLATED INTERFERON PLUS RIBAVIRIN TREATMENT OUTCOME IN CHRONIC HEPATITIS C GENOTYPE 4
41. Optical characterization of PMMA phase gratings written by a 387 nm femtosecond laser
42. Closed form solutions for the self-resonances in a short Josephson junction
43. 1318 FIBROSIS PROGRESSION IN PATIENTS WITH CHRONIC HEPATITIS C IS NOT INFLUENCED BY IL28B POLYMORPHISMS
44. P.1.29: A SUSTAINED VIROLOGICAL RESPONSE TO INTERFERON PREVENTS INSULIN RESISTANCE IN CHRONIC HEPATITIS C PATIENTS
45. T-36 Fibrosis progression in patients with chronic hepatitis C is not influenced by IL28B polymorphisms
46. T-42 A sustained virological response to interferon prevents insulin resistance in chronic hepatitis C patients
47. 291 INSULIN RESISTANCE DOES NOT PREDICT A RESPONSE TO PEGYLATED INTERFERON PLUS RIBAVIRIN IN CHRONIC HEPATITIS C PATIENTS: A SUB-ANALYSIS OF THE MIST STUDY
48. OC.03.3 INSULIN RESISTANCE DOES NOT PREDICT A RESPONSE TO PEGYLATED INTERFERON PLUS RIBAVIRIN IN CHRONIC HEPATITIS C PATIENTS: A SUB-ANALYSIS OF THE MIST STUDY
49. P.130 SAFETY AND EFFICACY OF PEG-IFN/RBV THERAPY IN PATIENTS WITH CHRONIC HEPATITIS C AND HIGH TITRES OF SERUM AUTOANTIBODIES: A SUB-ANALYSIS OF THE MIST STUDY
50. F.N.29 INSULIN RESISTANCE DOES NOT PREDICT A RESPONSE TO PEGYLATED INTERFERON PLUS RIBAVIRIN IN CHRONIC HEPATITIS C PATIENTS: A SUB-ANALYSIS OF THE MIST STUDY
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.